The regenerative process in the pancreas is of particular interest because diabetes results from an inadequate number of insulinproducing beta cells and pancreatic cancer may arise from the uncontrolled growth of progenitor/stem cells. Continued and substantial growth of islet tissue occurs after birth in rodents and humans, with additional compensatory growth in response to increased demand. In rodents there is clear evidence of pancreatic regeneration after some types of injury, with proliferation of preexisting differentiated cell types accounting for some replacement. Additionally, neogenesis or the budding of new islet cells from pancreatic ducts has been reported, but the existence and identity of a progenitor cell have been debated. We hypothesized that the progenitor cells are duct epithelial cells that after replication undergo a regression to a less differentiated state and then can form new endocrine and exocrine pancreas. To directly test whether ductal cells serve as pancreatic progenitors after birth and give rise to new islets, we generated transgenic mice expressing human carbonic anhydrase II (CAII) promoter: Cre recombinase (Cre) or inducible CreER TM to cross with ROSA26 loxP-Stop-loxP LacZ reporter mice. We show that CAII-expressing cells within the pancreas act as progenitors that give rise to both new islets and acini normally after birth and after injury (ductal ligation). This identification of a differentiated pancreatic cell type as an in vivo progenitor of all differentiated pancreatic cell types has implications for a potential expandable source for new islets for replenishment therapy for diabetes.
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diabetes ͉ islets of Langerhans ͉ lineage tracing R egeneration studies in mammals have focused on tissuespecific stem and progenitor cells. The regenerative process in the pancreas is of particular interest because diabetes results from an inadequate number of insulin-producing beta cells (1) and pancreatic cancer may arise from the uncontrolled growth of progenitor/stem cells (2) . Continued and substantial growth of islet tissue occurs after birth in rodents and humans, with additional compensatory growth in response to increased demand (3) . In rodents there is clear evidence of pancreatic regeneration after some types of injury, with proliferation of preexisting differentiated cell types accounting for some replacement (4-7). The mechanisms thought to be responsible for beta cell growth are replication of preexisting beta cells and differentiation from precursor cells or neogenesis, defined as islet hormone-positive cells budding from ducts. For the latter, differentiated ductal cells have been hypothesized to act as pancreatic progenitor cells (3, 8) . Whether adult stem cells contribute to this replacement is unclear.
In adult mice replication is the major mechanism for expanding the beta cell mass in pregnancy (9) , obesity/insulin resistance (10), or normal growth and aging. Using inducible RIPCreER TM mice to label the beta cells in adult mice, Dor et al. (11) confirmed the predominance of replication in the adult mouse and concluded that neogenesis does not occur after embryonic or early postnatal life and that solely self-duplication replenished beta cells. However, they neither examined the neonatal period nor clearly defined new lobes after partial pancreatectomy (12) , both of which are reported in rats to have highly active neogenesis. Additionally, it is difficult to conclude that new islet formation does not occur by marking a small fraction of cells and attempting to show a reduction in that fraction. Recently, Xu et al. (13) reported multipotent islet progenitor cells of unknown origin within the adult pancreas by showing the induction of neurogenin 3 after ductal ligation, isolating these neurogenin 3-positive cells and showing that they could differentiate to islet cells. Additionally, increased neogenesis is reported in adult rodents given exendin-4 (14) or betacellulin (15) , overexpressing IFN-␥ (16) or TGF-␣ (17), or after partial pancreatectomy (12) . The neogeneic pathway may be more important in adult humans for compensatory expansion of beta cell mass (1, 18, 19) because adult human beta cells have a very low replication (20) .
We hypothesize that the progenitors of these new islets were differentiated pancreatic ductal cells that regressed to a less differentiated phenotype after replication and then functioned as progenitors (Fig. 1A) (3, 8) . To test this hypothesis we took a direct approach of genetically marking ductal cells by generating transgenic (Tg) mice in which the human carbonic anhydrase II (CAII) promoter drives expression of Cre recombinase (CAIICre) or tamoxifen-inducible CAII-CreER TM (Fig. 1B) . CAII has been used previously as a marker of differentiated ductal cells (21) , which are distinct from the embryonic pancreatic progenitors. Starting late in gestation (embryonic day 18.5), CAII protein is expressed throughout the ductal tree in adult mice but not in the beta cells (22) . The human promoter was chosen to provide specificity for tracing the progeny of ductal cells because in human pancreas CAII is expressed only throughout the ductal tree (23) , whereas in rodents glucagon-expressing alpha cells also express CAII (22) . Thus, in these transgenic mice, if the transgene expression is faithful to that of the promoter, Cre recombinase should be expressed only in the ducts and not the islets. Here, we show that the CAII-expressing cells act as pancreatic progenitors that give rise to both new islets and acini after birth and after injury.
Results
We generated Tg mice in which the CAII promoter drives expression of CAII-Cre or inducible CAII-CreER TM (Fig. 1B) . Upon mating these transgenic mice with a reporter strain, ROSA26 loxP-Stop-loxP LacZ (R26R) (24) , Cre-mediated recombination should result in the permanent marking of CAIIexpressing cells and their progeny. Therefore, if the CAII transgene is specifically expressed only in ductal cells and they serve as pancreatic progenitors after birth, we should find ␤-galactosidase-positive cells not only in ducts but also in islets and acini in double-Tg mice; however, if they do not act as progenitors, only ducts should be labeled (Fig. 1B) .
To determine whether the transgene expression was faithful to that of the human promoter, we undertook several assessments. In double-heterozygous CAII-R26R mice, ␤-galactosidase immunostaining was seen throughout the ducts at birth (Fig. 2 A-C and H) and only rarely at embryonic day 18.5 [supporting information (SI) Fig. S1 ]; these structures were confirmed as ducts by morphology and by immunostaining (Fig. S2) . At birth ␤-galactosidase expression in pancreatic cell types was restricted to the ducts: its expression was not found in insulin-positive beta cells ( Fig. 2 A and B and Figs. S3 and S4), glucagon-positive alpha cells ( Fig. 2C and Fig. S5 ), or acini ( Fig. 2 A-C and Figs. S3-S5 ). CAII is expressed in both the peripheral and central nervous systems (25) but is irrelevant to the current analysis, and CAII neural expression serves as positive control ( Fig. 2 A and B) . However, because ganglia are intimately associated with islets in the mouse (26), we could not use RNA from isolated islets to exclude the possibility of Cre expression in beta cells of our mice. Therefore, we crossed our Tg mice with MIP-GFP mice (27) , dispersed the excised pancreas, and FACS purified GFP ϩ beta cells from 1-day-old, 2-week-old, 4-week-old, and 8-week-old CAII-Cre:MIP-GFP mice (Fig. S6 ). In FACS-purified beta cells, no CAII or Cre mRNA was found, even after 40 cycles of PCR amplification, but this mRNA was found in both Tg kidneys (22) and GFP Ϫ pancreatic cells ( Fig. 2 D and F) . The RNA integrity of these samples was verified by probing for pdx1 at 28 cycles (Fig. 2E ). To further confirm the specificity of transgene expression, we immunostained for Cre recombinase in pancreas from CAII-Cre and CAII-CreER TM mice: the only Cre-positive cells were in ducts ( Fig. 2 G-J) and ganglia ( Fig. 2 K and L) . Thus, transgene expression appears appropriately restricted.
Pancreatic weight increases about 15-fold between birth and 4 weeks of age (28) . Using data from our longitudinal study of beta cell mass and its determinants (28), we estimated that more than 30% of the new beta cells seen at day 31 did not arise from replication of preexisting beta cells (3) . Therefore, pancreases of double-heterozygous CAII-Cre:R26R mice were analyzed at day 0 and at 4 weeks to determine the contribution of new islets or lobes during normal postnatal development (Fig. 3A) . At 4 weeks ␤-galactosidase expression was found in many ducts, patches of acinar cells, and some islets ( Fig. 3 B-D) . Within marked islets, both beta and alpha cells were ␤-galactosidase-positive ( Fig. 3 with few, if any, in some lobes, and as many as 50% in others (Fig.  3D) . CAII expression is initiated in ducts only about embryonic day 18, when a large founder population of islets and acini have already been specified; thus, only a fraction of islets and acini are expected to be duct-derived after birth. The ␤-galactosidase-positive islets as a proportion of total islets showed a substantial increase in the number of marked islets from day 0 to 4 weeks of age (Fig. 3E) . At birth few marked islets were seen. Of 189 scored islets from 8 double-Tg mice, 14 islets had ␤-galactosidase-positive cells; of these, 11 were in 1 animal. We consider this mouse an outlier because there were numerous marked islets (with multiple ␤-galactosidase-positive insulin or glucagon-positive cells), ducts, and acinar cells (data not shown), indicating an earlier CAII expression; excluding this animal, only 1.7% of islets were marked at day 0. However, at 4 weeks, 143 of 383 islets from 8 animals (37.8%; range, 30-64%) were marked. Thus, formation of new islets and acini from ductal progenitors occurs during the neonatal period. Although we cannot definitively rule out a transient spike of (Fig. 2  F-L) , and such expression in 3 different pancreatic cell types (acinar, beta, and alpha) would be unlikely.
To test the ability of adult pancreatic ductal cells as pancreatic progenitors, we used inducible CAII-CreER TM mice in a regeneration model (Fig. 1B) . In CreER TM mice, Cre-mediated recombination is tamoxifen-dependent, providing a pulse-chase type of analysis. Both acinar formation and neogenesis are reported in various regeneration models-for example, partial pancreatectomy, cellophane wrapping (30) , and duct ligation (4, 13) . Ductal ligation has the advantage of having regeneration localized to the ligated (distal) portion with little to none in the nonligated (proximal) portion (4), allowing comparison of labeling in regenerated and nonregenerated tissue within the same pancreas. To avoid marking the neonatal neogenesis, we implanted tamoxifen pellets in double-CAII-CreER TM :R26R mice at 4 weeks of age for 3-week labeling. Animals underwent ductal ligation at 8 weeks and were killed at 10 weeks (Fig. 4A) .
Wild-type (10-week-old) animals (Fig. 4B ) had a few, lowintensity, ␤-galactosidase-positive beta cells (5.1% Ϯ 1.2% marked islets, five animals; 1.3% Ϯ 1.2% positive beta cells, 3 animals), with no differences between ligated and nonligated portions. We interpret these to be false-positives independent of CAII promoter expression and resulting from antibody binding to the low level of endogenous ␤-galactosidase expressed in adult beta cells (31) . Similarly low levels of marked islets in 6-monthold wild-type or untreated double-Tg mice further support that false-positives are independent of CAII promoter expression (Fig. 4B) . Tg controls (with tamoxifen but no ligation or without tamoxifen but with ligation) (7.4% Ϯ 1.8% islets, n ϭ 5; 0.9% Ϯ 0.5% positive beta cells, 4 animals) did not differ from wild-type animals. The nonligated portions (Fig. 4C ) of tamoxifen-treated double-Tg mice had duct cells and an occasional islet or acinus expressing ␤-galactosidase (Tg: 12.1% Ϯ 1.9% positive islets, P Ͻ 0.01 vs. wild type; 5.5% Ϯ 2.0% positive beta cells, n ϭ 4 animals; Fig. 4B) ; the percentage of marked islets differed from wild type, possibly reflecting a low amount of neogenesis that occurred since the start of the tamoxifen treatment. In contrast, in the ligated portions we found considerably more ␤-galactosidase-marked islets and acini (42.4% Ϯ 1.2% positive islets in the distal, regenerated pancreas compared with nonligated pancreas of the same animals (P Ͻ 0.002, n ϭ 4); the ligated portion had 23.6% Ϯ 2.2% marked beta cells (Fig. 4 D, F, and  G) . Occasionally, a lobe had many marked acinar cells, suggesting a new lobe (Fig. 4E) . No more than 30-50% of total ductal cells (Fig. 4D) were marked, as frequently seen in other Cre recombinase driver lines, thus decreasing the chance of seeing every duct-to-endocrine transition.
Discussion
In these studies we show that the CAII-expressing pancreatic cells act as pancreatic progenitors in neonates and adults. Neural tissue was marked, and so the unlikely possibility that neuronal cells, whether differentiated ones of the enteric nervous system or undifferentiated Phox2b-expressing neural precursors from the neural crest, act as the pancreatic progenitors cannot be completely ruled out. Nonetheless, ductal cells are likely to be the progenitors because: (i) they express CAII in both rodent and human pancreas and are the only pancreatic-specific cells expressing the transgene at birth; (ii) mature ductal cells partially dedifferentiate after replication (3, 8) ; (iii) many ductal genes are expressed in the newly formed beta cells after partial pancreatectomy and at birth (3); (iv) islet cells form from human pancreatic ductal cells in vitro and in grafts (32, 33) . Our data provide strong support to the concept of a shared lineage of ductal, acinar, and islet cells after birth. Although the true progenitors may be only a subpopulation within the ductal epithelium, the transient expression of PDX1 protein, a marker of embryonic pancreatic progenitors, in all replicating duct cells (8) is consistent with most, if not all, having the potential. A similar paradigm for replenishment of cells by dedifferentiation/ redifferentiation of a mature phenotype to other organ-specific phenotypes has been reported in the liver (34) and kidney (35) .
In summary, we showed by direct lineage tracing that pancreatic CAII-expressing cells give rise to new islet and acinar cells normally after birth and after injury. This identification of a differentiated pancreatic cell type as an in vivo progenitor of all differentiated pancreatic cell types has implications for a potential expandable source for new islets for replenishment therapy for diabetes. Although our emphasis has been on the endocrine pancreas, the implications of our findings extend to pancreatic cancer, which may arise from the uncontrolled growth of progenitor/stem cells.
Methods
Generation of Transgenic Animals. Carbonic anhydrase II (CAII)Cre and CreER TM constructs were generated with 1.6-kb human CAII promoter from pCAIIXbaITtH111I (a gift from T. Takeya, Nara Institute of Science and Technology, Nara, Japan) as described previously (31) , and Cre or CreER TM coding sequence from pPDXPB CreER TM (36) . Plasmid construction was confirmed by restriction mapping and sequencing of critical regions. DNA was digested with KpnI and AflII, and the CAII-Cre or CreER TM transgenes were isolated and microinjected into the fertilized eggs of C57BL/6 ϫ C57BL/6 mice (Joslin/Brigham and Women's Hospital Transgenic Core). Potential founder animals were screened by PCR and by Southern blotting analysis by using EcoRI digestion and a Crespecific probe. For PCR, mouse tail DNA was amplified by 32 cycles by using 2 independent sets of Cre-specific primers: 5Ј-TGATGGACATGTTCAGG-GATCG-3Ј and 5Ј-ACCGTCAGTACGTGAGATATCTT-3Ј; 5Ј-ACCTGAAGATGT-TCGCGATTATCT-3Ј and 5Ј-GATCATCAGCTACACCAGAGAC-3Ј. All procedures with mice were approved by the Joslin Diabetes Center's Institutional Animal Care and Use Committee. CAII Cre or CreER TM transgenic mice were crossed to ROSA26 reporter mice (R26R) (24) . The sequences of the primers to detect R26R alleles were as published (24) .
For genetic marking experiments, CreER TM -R26R double-Tg mice had 3-week slow-release (1-2 mg/day) tamoxifen (TM) pellet (Innovative Research of America) implanted. At 4 weeks after implant (washout period of 8 days), these animals had duct ligation. As controls, both double-Tg and R26R-only littermates received tamoxifen without duct ligation, no tamoxifen with duct ligation, or neither tamoxifen nor duct ligation. Two weeks after ligation, animals were killed. Pancreases were excised, fixed in cold 4% paraformaldehyde for 2 h, incubated in 30% sucrose overnight at 4°C, embedded in Tissue-Tek OCT compound (Sakura Finetechnical ), and cut into 7-to 10-m sections.
Sorting of Beta Cells for Verification of Cre Recombinase Expression. CAII-Cre mice were crossed with homozygous MIP-GFP mice on C7BL/6 background. Under anesthesia, the pancreases of mice at 0, 2, 4, and 8 weeks of age were excised, minced, and incubated in collagenase solution (Liberase RI; Roche) for 20 min at 37°C. After washing in PBS, digested tissue was dispersed by exposure to 1 mg/mL bovine pancreas trypsin (Sigma) and 30 g/mL DNase I (Roche) in PBS for 15 min at 37°C. After wash with RPMI 1640 plus 10% FBS, they were spun down and resuspended in less than 1 mL of PBS. Cells were passed through a 40-m filter and stained with propidium iodide (Sigma). All samples were analyzed on a MoFlo cell sorter with Summit software (Cytomation) with gates for live cells (propidium iodide) and beta cells (GFP).
RNA Isolation and Reverse Transcription-PCR.
Total RNA was extracted from freshly sorted beta cells and whole kidneys of the same animals by using an RNAeasy Micro kit (Invitrogen) and TRIzol (GIBCO), respectively. Beta cell cDNA was synthesized by a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), and kidney cDNA by SuperScript reverse transcriptase (Life Technologies). The cDNAs were amplified by PCR using specific oligonucleotides for hypoxanthine phosphoribosyltransferase (HPRT), insulin, Cre, and CAII. The primer sequences were: HPRT, 5Ј-GGGGGCTATAAGTTCTTTGC-3Ј and 5Ј-TCCAACACTTCGAGAGGTCC-3Ј; insulin, 5Ј-GACCAGCTATAATCA-GAGACC-3Ј and 5Ј-AGTTGCAGTAGTTCTCCAGCT-3Ј, the first set for Cre given above, and CAII (22) . Total RNA without reverse transcription served as a negative control.
Immunohistochemistry. Tyramide signal amplification system (Renaissance; Perkin-Elmer) was used for anti-␤-galactosidase antibody (1:8,000; Cappel); biotin-SP-conjugated donkey anti-rabbit IgG serum (1:400; Jackson ImmunoResearch), streptavidin-horseradish peroxidase (1:100; Perkin-Elmer), and fluorescein-tyramide (1:50) were sequentially applied. Subsequently, guinea pig anti-insulin antibody (1:200; Linco Research), guinea pig anti-glucagon antibody (1:3,000; a gift from M. Appel, University of Massachusetts Medical School, Worcester, MA), or mouse anti-pan-cytokeratin was incubated overnight at 4°C and visualized with a secondary antibody conjugated to Texas red fluorochrome; mouse anti-pan-cytokeratin was incubated overnight, followed by biotinylated goat anti-mouse Ig (1:800) and Cy3-strepavidin (1:800). For Cre localization on adjacent sections, rabbit anti-Cre recombinase (1:800; Novagen) was incubated overnight, followed by biotinylated goat anti-rabbit IgG (1:800) and Cy3-strepavidin (1:800). For identifying ganglia (37), goat anti-BMPR1A (1:100; Santa Cruz Biotechnology) was applied to sections previously stained for Cre and visualized with FITC-conjugated anti-goat IgG . In embryonic day 18.5 (E18.5) pancreas, ␤-galactosidase is expressed only rarely in ducts. At E18.5 ␤-galactosidase (green) is expressed strongly in ganglia (g) and only faintly in some of the ducts (d, upper right) and not in the insulin-positive cells (red); the same image in graytone (Right) labeled and is given to distinguish the tissue organization. The background was enhanced for both images to distinguish the tissue organization. S6 . Sorting of beta cells for verification of lack of Cre recombinase expression. From CAII-CRE:MIP-GFP mice, the pancreases were excised and dispersed for FACS purification based on the GFP expression in all beta cells. After gating for single cells (pulse width vs. forward scatter), samples were analyzed on a MoFlo cell sorter (Cytomation) with gates for live cells (propidium iodide) and beta cells (GFP). This sorting was then repeated to obtain purified beta cells, from which the RNA was extracted.
